Eyenovia, Inc. (EYEN)
Eyenovia, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $7.56, up 3.99% on the session, giving a market capitalisation of $38.6M. On trailing twelve-month figures it carries a trailing P/E of -1.14, a net margin of -4505916.6%. Its beta of 1.00 implies it has historically moved more than the broad market.
Eyenovia, Inc., a New York-based company established in 2014 (originally incorporated as PGP Holdings V, Inc.), functions as a clinical-stage pharmaceutical firm specializing in ophthalmology. The company utilizes its exclusive microdose array print platform technology and the Optejet branded targeted ocular delivery system to formulate innovative eye treatments. Its primary focus for research and development lies in addressing progressive myopia (nearsightedness), age-related near vision impairment (presbyopia), and pharmacologically induced pupil dilation for eye examinations. Eyenovia's developmental pipeline includes several advanced candidates, all currently undergoing Phase III clinical trials: MicroLine: Designed to enhance near vision for individuals with presbyopia. MicroPine: Aimed at slowing the progression of nearsightedness in pediatric patients. MydCombi: A microdose fixed-combination treatment intended for pharmaceutical mydriasis. Furthermore, Eyenovia has forged strategic alliances for product commercialization. It maintains a licensing agreement with Bausch Health Ireland Limited for the development and commercialization of MicroPine across the United States and Canada. Additionally, an agreement with Arctic Vision (Hong Kong) Limited covers the development and commercialization of both MicroPine and MicroLine in the markets of China and South Korea.
Eyenovia, Inc. is most often compared with the following Healthcare names: